OBJECTIVE: To compare glycemic control, quality of life, and pregnancy outcomes of women usinginsulin pumps and multiple daily injection therapy (MDI) during the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT). RESEARCH DESIGN AND METHODS: This was a prespecified analysis of CONCEPTT involving 248 pregnant women from 31 centers. Randomization was stratified for pump versus MDI and HbA1c. The primary outcome was change in HbA1c from randomization to 34 weeks' gestation. Key secondary outcomes were continuous glucose monitoring (CGM) measures, maternal-infant health, and patient-reported outcomes. RESULTS: At baseline, pump users were more often in stable relationships (P = 0.003), more likely to take preconception vitamins (P = 0.03), and less likely to smoke (P = 0.02). Pump and MDI users had comparable first-trimester glycemia: HbA1c 6.84 ± 0.71 vs. 6.95 ± 0.58% (51 ± 7.8 vs. 52 ± 6.3 mmol/mol) (P = 0.31) and CGM time in target (51 ± 14 vs. 50 ± 13%) (P = 0.40). At 34 weeks, MDI users had a greater decrease in HbA1c (-0.55 ± 0.59 vs. -0.32 ± 0.65%, P = 0.001). At 24 and 34 weeks, MDI users were more likely to achieve target HbA1c (P = 0.009 and P = 0.001, respectively). Pump users had more hypertensive disorders (P = 0.011), mainly driven by increased gestational hypertension (14.4 vs. 5.2%; P = 0.025), and more neonatal hypoglycemia (31.8 vs. 19.1%, P = 0.05) and neonatal intensive care unit (NICU) admissions >24 h (44.5 vs. 29.6%; P = 0.02). Pump users had a larger reduction in hypoglycemia-related anxiety (P = 0.05) but greater decline in health/well-being (P = 0.02). CONCLUSIONS: In CONCEPTT, MDI users were more likely to have better glycemic outcomes and less likely to have gestational hypertension, neonatal hypoglycemia, and NICU admissions than pump users. These data suggest that implementation of insulin pump therapy is potentially suboptimal during pregnancy.
RCT Entities:
OBJECTIVE: To compare glycemic control, quality of life, and pregnancy outcomes of women using insulin pumps and multiple daily injection therapy (MDI) during the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT). RESEARCH DESIGN AND METHODS: This was a prespecified analysis of CONCEPTT involving 248 pregnant women from 31 centers. Randomization was stratified for pump versus MDI and HbA1c. The primary outcome was change in HbA1c from randomization to 34 weeks' gestation. Key secondary outcomes were continuous glucose monitoring (CGM) measures, maternal-infant health, and patient-reported outcomes. RESULTS: At baseline, pump users were more often in stable relationships (P = 0.003), more likely to take preconception vitamins (P = 0.03), and less likely to smoke (P = 0.02). Pump and MDI users had comparable first-trimester glycemia: HbA1c 6.84 ± 0.71 vs. 6.95 ± 0.58% (51 ± 7.8 vs. 52 ± 6.3 mmol/mol) (P = 0.31) and CGM time in target (51 ± 14 vs. 50 ± 13%) (P = 0.40). At 34 weeks, MDI users had a greater decrease in HbA1c (-0.55 ± 0.59 vs. -0.32 ± 0.65%, P = 0.001). At 24 and 34 weeks, MDI users were more likely to achieve target HbA1c (P = 0.009 and P = 0.001, respectively). Pump users had more hypertensive disorders (P = 0.011), mainly driven by increased gestational hypertension (14.4 vs. 5.2%; P = 0.025), and more neonatal hypoglycemia (31.8 vs. 19.1%, P = 0.05) and neonatal intensive care unit (NICU) admissions >24 h (44.5 vs. 29.6%; P = 0.02). Pump users had a larger reduction in hypoglycemia-related anxiety (P = 0.05) but greater decline in health/well-being (P = 0.02). CONCLUSIONS: In CONCEPTT, MDI users were more likely to have better glycemic outcomes and less likely to have gestational hypertension, neonatal hypoglycemia, and NICU admissions than pump users. These data suggest that implementation of insulin pump therapy is potentially suboptimal during pregnancy.
Authors: Verónica Perea; Maria José Picón; Ana Megia; Maria Goya; Ana Maria Wägner; Begoña Vega; Nuria Seguí; Maria Dolores Montañez; Irene Vinagre Journal: Diabetologia Date: 2022-05-12 Impact factor: 10.460
Authors: Basak Ozaslan; Carol J Levy; Yogish C Kudva; Jordan E Pinsker; Grenye O'Malley; Ravinder Jeet Kaur; Kristin Castorino; Camilla Levister; Mari Charisse Trinidad; Donna Desjardins; Mei Mei Church; Mitchell Plesser; Shelly McCrady-Spitzer; Selassie Ogyaadu; Kristen Nelson; Corey Reid; Sunil Deshpande; Walter K Kremers; Francis J Doyle; Barak Rosenn; Eyal Dassau Journal: Diabetes Technol Ther Date: 2022-04-26 Impact factor: 7.337
Authors: Carol J Levy; Nicole C Foster; Stephanie N DuBose; Shivani Agarwal; Sarah K Lyons; Anne L Peters; Gabriel I Uwaifo; Linda A DiMeglio; Jennifer L Sherr; Sarit Polsky Journal: J Diabetes Sci Technol Date: 2020-11-20
Authors: Sarit Helman; Tamarra M James-Todd; Zifan Wang; Andrea Bellavia; Jennifer A Wyckoff; Shanti Serdy; Elizabeth Halprin; Karen O'Brien; Tamara Takoudes; Munish Gupta; Thomas F McElrath; Florence M Brown Journal: J Perinatol Date: 2020-06-02 Impact factor: 2.521
Authors: Grenye O'Malley; Basak Ozaslan; Carol J Levy; Kristin Castorino; Donna Desjardins; Camilla Levister; Shelly McCrady-Spitzer; Mei Mei Church; Ravinder Jeet Kaur; Corey Reid; Walter K Kremers; Francis J Doyle; Mari Charisse Trinidad; Barak Rosenn; Jordan E Pinsker; Yogish C Kudva; Eyal Dassau Journal: Diabetes Technol Ther Date: 2021-08-17 Impact factor: 7.337